Asarfi Hospital

  • Market Cap: Micro Cap
  • Industry: Hospital
  • ISIN: INE0DN001027
  • NSEID:
  • BSEID: 543943
INR
252.80
7.8 (3.18%)
BSENSE

May 08

BSE+NSE Vol: 48000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationUpcoming Result: Asarfi Hospital will declare its result soon on 11 May 2026
stock-recommendationMojo Score Change: Asarfi Hospital has changed its score on 06 May 2026. Click here to unlock latest mojo score!
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

48.0 k (-42.99%) Volume

Shareholding (Mar 2026)

FII

0.00%

Held by 0 FIIs

DII

2.40%

Held by 0 DIIs

Promoter

61.17%

What does Asarfi Hospital do?

06-Jun-2025

Asarfi Hospital Ltd is a micro-cap company in the hospital industry, incorporated in 2005 and converted to a public limited company in 2012. As of March 2025, it reported net sales of 34 Cr and a net profit of 4 Cr, with a market cap of Rs 268 Cr.

Overview: <BR>Asarfi Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Asarfi Hospital Limited was originally incorporated as a Private Limited Company on October 4, 2005, under the name "Asarfi Hospital Private Limited." The company later converted its status to Public Limited and changed its name to "Asarfi Hospital Limited" on February 08, 2012. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 34 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 268 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.20 <BR>Return on Equity: 15.58% <BR>Price to Book: 3.76 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

View full answer

Has Asarfi Hospital declared dividend?

06-Jun-2025

No Dividend History Available

What is the technical trend for Asarfi Hospital?

09-Jun-2025

As of May 19, 2025, Asarfi Hospital's technical trend is bullish, supported by a positive MACD and moving averages, although the weekly RSI indicates some potential weakness in momentum.

As of 19 May 2025, the technical trend for Asarfi Hospital has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate bullish momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the strength of the current trend. However, the weekly RSI is bearish, suggesting some potential weakness in momentum. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish MACD and moving averages.

View full answer

Who are the peers of the Asarfi Hospital?

16-Jul-2025

Asarfi Hospital's peers include GPT Healthcare, KMC Speciality, Aashka Hospitals, and others, with varying management risks and growth rates. Asarfi Hospital has a good management risk and a 1-year return of 92.36%, outperforming its peers.

Peers: The peers of Asarfi Hospital are GPT Healthcare, KMC Speciality, Abate As Indust, Aashka Hospitals, Aprameya Enginee, Unihealth Hosp, Chandan Healthca, Nephro Care, KHFM Hospitality, and Maitreya Medica.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare and Chandan Healthca, while Average management risk is found at KMC Speciality and KHFM Hospitality. Good management risk is noted at Asarfi Hospital, Aprameya Enginee, Unihealth Hosp, and Nephro Care, while Below Average management risk is present at Aashka Hospitals. Growth is Excellent at Aprameya Enginee and Nephro Care, Below Average at GPT Healthcare, KMC Speciality, Asarfi Hospital, Aashka Hospitals, and KHFM Hospitality, and does not qualify for Abate As Indust. Capital Structure is Excellent at GPT Healthcare and KMC Speciality, Good at Asarfi Hospital, Nephro Care, and Chandan Healthca, Below Average at Aprameya Enginee, Unihealth Hosp, Aashka Hospitals, and KHFM Hospitality, and does not qualify for Abate As Indust.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Abate As Indust at 46.07%, while the lowest is KMC Speciality at -19.73%. Asarfi Hospital's 1-year return is 92.36%, which is significantly higher than both. Additionally, KMC Speciality, Aashka Hospitals, and KHFM Hospitality have negative six-month returns.

View full answer

Who are in the management team of Asarfi Hospital?

16-Jul-2025

As of March 2023, the management team of Asarfi Hospital includes Udai Pratap Singh (Managing Director), Madhuri Singh (Executive Director), Sukanti Kumar Das (Director), Amit Kumar Barnwal (Independent Director), Rajkumari Sharma (Independent Director), and Seepika Gupta (Company Secretary & Compliance Officer). Each member contributes to the hospital's governance and operations.

As of March 2023, the management team of Asarfi Hospital includes the following individuals:<BR><BR>1. Udai Pratap Singh - Managing Director<BR>2. Madhuri Singh - Executive Director<BR>3. Sukanti Kumar Das - Director<BR>4. Amit Kumar Barnwal - Independent Director<BR>5. Rajkumari Sharma - Independent Director<BR>6. Seepika Gupta - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and operational oversight of the hospital.

View full answer

Who are the top shareholders of the Asarfi Hospital?

17-Jul-2025

The top shareholders of Asarfi Hospital include Harendra Singh with 18.78%, followed by public shareholder Gopal Singh at 2.4%. Individual investors collectively own 30.86% of the shares, with no pledged promoter holdings or involvement from mutual funds or foreign institutional investors.

The top shareholders of Asarfi Hospital primarily consist of the promoters, with Harendra Singh holding the largest stake at 18.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors involved. The highest public shareholder is Gopal Singh, who holds 2.4%. Additionally, individual investors collectively own 30.86% of the shares.

View full answer

How big is Asarfi Hospital?

24-Jul-2025

As of 24th July, Asarfi Hospital Ltd has a market capitalization of 261.00 Cr, with net sales of 110.87 Cr and a net profit of 6.01 Cr over the last four quarters. Shareholder's funds are 70.41 Cr, and total assets amount to 154.09 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Asarfi Hospital Ltd has a market capitalization of 261.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 110.87 Cr, while the sum of Net Profit for the same period is 6.01 Cr.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2024. Shareholder's Funds stand at 70.41 Cr, and Total Assets amount to 154.09 Cr.

View full answer

How has been the historical performance of Asarfi Hospital?

15-Nov-2025

Asarfi Hospital experienced significant growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 120.57 Cr and profit after tax increasing to 10.58 Cr. However, cash flow from operating activities turned negative, indicating challenges in cash management despite strong revenue performance.

Answer:<BR>The historical performance of Asarfi Hospital shows significant growth from the previous year, with net sales increasing from 84.40 Cr in Mar'24 to 120.57 Cr in Mar'25. Total operating income mirrored this growth, rising to 120.57 Cr from 84.40 Cr. The total expenditure also increased, from 68.35 Cr to 97.01 Cr, primarily driven by higher raw material costs and other expenses. Operating profit (PBDIT) rose to 31.08 Cr from 17.72 Cr, while profit before tax improved from 6.24 Cr to 14.31 Cr. Consequently, profit after tax saw a substantial increase from 4.16 Cr to 10.58 Cr, resulting in an earnings per share (EPS) growth from 2.11 to 5.38. <BR><BR>In terms of balance sheet performance, shareholder's funds increased to 80.98 Cr from 70.41 Cr, and total liabilities rose to 163.89 Cr from 154.09 Cr. Long-term borrowings also increased significantly from 17.45 Cr to 33.83 Cr. Current assets improved to 58.48 Cr from 45.60 Cr, with notable increases in sundry debtors and inventories. However, cash flow from operating activities turned negative, dropping from 26.00 Cr to -4.00 Cr, while cash flow from financing activities decreased from 36.00 Cr to 12.00 Cr. Overall, Asarfi Hospital demonstrated strong revenue and profit growth, despite challenges in cash flow management.

View full answer

Is Asarfi Hospital overvalued or undervalued?

17-Nov-2025

As of November 14, 2025, Asarfi Hospital is considered overvalued with a PE ratio of 31.38 and an EV to EBITDA of 16.34, despite strong stock performance, indicating it may not be an attractive investment compared to peers like Apollo Hospitals and Max Healthcare.

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which suggests growth potential relative to its valuation. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 63.77 and an EV to EBITDA of 33.53, while Max Healthcare is marked as very expensive with a PE of 89.07. Despite the recent strong stock performance, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, the elevated valuation metrics indicate that Asarfi Hospital may not present an attractive investment opportunity at current levels.

View full answer

When is the next results date for Asarfi Hospital Ltd?

03-Feb-2026

The next results date for Asarfi Hospital Ltd is 09 February 2026.

The next results date for Asarfi Hospital Ltd is scheduled for 09 February 2026.

View full answer

Are Asarfi Hospital Ltd latest results good or bad?

10-Feb-2026

Asarfi Hospital Ltd's latest Q3 FY26 results are strong, with a net profit of ₹5.42 crores, up 102.24% year-on-year, and revenue growth of 40.16% to ₹46.10 crores. The company has improved its operating and PAT margins, indicating robust operational efficiency and positioning it well in the healthcare sector.

Asarfi Hospital Ltd's latest results for Q3 FY26 are quite strong and indicate a positive performance. The company reported a net profit of ₹5.42 crores, which is a remarkable increase of 102.24% year-on-year. Additionally, revenue for the same quarter reached ₹46.10 crores, reflecting a growth of 40.16% compared to the previous year.<BR><BR>The operating margin also improved, reaching 21.93%, the highest in seven quarters, and the PAT margin increased to 11.76%, up by 361 basis points year-on-year. This demonstrates the company's ability to enhance operational efficiency while scaling its operations.<BR><BR>Overall, the financial performance showcases impressive growth and operational excellence, positioning Asarfi Hospital as a strong player in the healthcare sector. The stock has also performed exceptionally well, significantly outperforming the broader market and its peers over the past year.

View full answer

Should I buy, sell or hold Asarfi Hospital Ltd?

07-May-2026

Why is Asarfi Hospital Ltd falling/rising?

09-May-2026

As of 08-May, Asarfi Hospital Ltd's stock price is at Rs 252.80, reflecting a 3.18% increase, with strong performance over various periods, including a 34.40% year-to-date rise. Despite a decline in investor participation, the stock remains liquid and shows robust investor confidence, significantly outperforming the Sensex.

As of 08-May, Asarfi Hospital Ltd's stock price is rising, currently at Rs 252.80, reflecting a change of Rs 7.8 or 3.18%. The stock has shown strong performance over various periods, with a remarkable increase of 17.04% over the past week and 31.46% over the past month, significantly outperforming the Sensex, which has seen only a 0.54% increase in the same week and a decline of 0.30% over the month.<BR><BR>Additionally, the stock has a year-to-date increase of 34.40%, while the Sensex has decreased by 9.26% during the same timeframe. Over the past year, Asarfi Hospital Ltd has surged by 163.31%, contrasting sharply with the Sensex's decline of 3.74%. This strong upward trend indicates robust investor confidence in the company.<BR><BR>On the day of reporting, the stock was close to its 52-week high, just 0.96% away from Rs 256.95, and it reached an intraday high of Rs 255, marking a 4.08% increase. Furthermore, Asarfi Hospital Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive technical indicator.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 35.02% against the 5-day average. Despite this, the stock remains liquid enough for trading, indicating that the price rise is supported by strong demand relative to the broader market performance. Overall, the combination of significant price increases, strong historical performance, and favorable technical indicators contributes to the rising stock price of Asarfi Hospital Ltd.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.96 times

 
2

With a growth in Net Profit of 29.05%, the company declared Outstanding results in Dec 25

3

With ROCE of 14.5, it has a Attractive valuation with a 4.1 Enterprise value to Capital Employed

4

Majority shareholders : Promoters

 
5

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 482 Cr (Micro Cap)

stock-summary
P/E

31.00

stock-summary
Industry P/E

62

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.40

stock-summary
Return on Equity

17.42%

stock-summary
Price to Book

5.14

Revenue and Profits:
Net Sales:
46 Cr
(Quarterly Results - Dec 2025)
Net Profit:
5 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
35.55%
0%
35.55%
6 Months
76.78%
0%
76.78%
1 Year
163.31%
0%
163.31%
2 Years
220.81%
0%
220.81%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Asarfi Hospital for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Closure of Trading Window

27-Mar-2026 | Source : BSE

In term of the provision of the securities and Exchange Board of India (PIT) Regulation2015 as amended from to time and Prohibition of Insider trading policy (the Policy).The Trading Window for the dealing in the securities of the company will be closed for all designated person and their Immediate Relative from April01 2026 and the same will remain closed until 48 hours after the declaration of Audited Financial Result of the Company for the quarter ended and financial Year ended March 31 2026.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

10-Feb-2026 | Source : BSE

Outcome of Press Release/Media Release Under Regulation 30 of SEBI ( Listing Obligation and Disclosure Requirements) Regulation 2015.

Submission Of Unaudited Financial Results For The Quarter Ended 31St December 2025

09-Feb-2026 | Source : BSE

We wish to inform you that the Board of Director of Asarfi Hospital Limited at its meeting held today i.e. 09-February26 has considered and approved the unaudited standalone and consolidated financial result of the company for the quarter ended 31 December25.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

11 May 2026

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
22.70%
EBIT Growth (5y)
14.76%
EBIT to Interest (avg)
3.30
Debt to EBITDA (avg)
2.00
Net Debt to Equity (avg)
0.40
Sales to Capital Employed (avg)
0.92
Tax Ratio
27.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.40%
ROCE (avg)
8.69%
ROE (avg)
13.08%

Valuation key factors

Factor
Value
P/E Ratio
31
Industry P/E
62
Price to Book Value
5.34
EV to EBIT
28.30
EV to EBITDA
17.33
EV to Capital Employed
4.11
EV to Sales
3.35
PEG Ratio
0.19
Dividend Yield
NA
ROCE (Latest)
14.51%
ROE (Latest)
17.42%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Harendra Singh (18.78%)

Highest Public shareholder

Gopal Singh (2.4%)

Individual Investors Holdings

30.63%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 2.70% vs 25.81% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 29.05% vs 34.62% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "46.10",
          "val2": "44.89",
          "chgp": "2.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10.11",
          "val2": "8.87",
          "chgp": "13.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.25",
          "val2": "1.07",
          "chgp": "16.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5.42",
          "val2": "4.20",
          "chgp": "29.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.93%",
          "val2": "19.76%",
          "chgp": "2.17%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2025 is 24.17% vs 22.01% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Mar 2025 is 47.86% vs 107.01% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "66.78",
          "val2": "53.78",
          "chgp": "24.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.22",
          "val2": "11.62",
          "chgp": "5.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.52",
          "val2": "1.56",
          "chgp": "61.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "6.55",
          "val2": "4.43",
          "chgp": "47.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.30%",
          "val2": "21.61%",
          "chgp": "-3.31%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 0.34% vs 5.91% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -5.30% vs -29.90% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "86.67",
          "val2": "86.38",
          "chgp": "0.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18.60",
          "val2": "18.22",
          "chgp": "2.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.74",
          "val2": "2.58",
          "chgp": "6.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.15",
          "val2": "7.55",
          "chgp": "-5.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.46%",
          "val2": "21.09%",
          "chgp": "0.37%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 42.86% vs 19.38% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 160.81% vs -47.51% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "120.57",
          "val2": "84.40",
          "chgp": "42.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "23.85",
          "val2": "16.09",
          "chgp": "48.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.08",
          "val2": "2.69",
          "chgp": "51.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "10.98",
          "val2": "4.21",
          "chgp": "160.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.78%",
          "val2": "19.06%",
          "chgp": "0.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
46.10
44.89
2.70%
Operating Profit (PBDIT) excl Other Income
10.11
8.87
13.98%
Interest
1.25
1.07
16.82%
Exceptional Items
0.00
0.00
Consolidate Net Profit
5.42
4.20
29.05%
Operating Profit Margin (Excl OI)
21.93%
19.76%
2.17%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 2.70% vs 25.81% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 29.05% vs 34.62% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Sep'24
Change(%)
Net Sales
66.78
53.78
24.17%
Operating Profit (PBDIT) excl Other Income
12.22
11.62
5.16%
Interest
2.52
1.56
61.54%
Exceptional Items
0.00
0.00
Standalone Net Profit
6.55
4.43
47.86%
Operating Profit Margin (Excl OI)
18.30%
21.61%
-3.31%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Mar 2025 is 24.17% vs 22.01% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Mar 2025 is 47.86% vs 107.01% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary

Dec'24
Dec'25
Change(%)
Net Sales
86.67
86.38
0.34%
Operating Profit (PBDIT) excl Other Income
18.60
18.22
2.09%
Interest
2.74
2.58
6.20%
Exceptional Items
0.00
0.00
Standalone Net Profit
7.15
7.55
-5.30%
Operating Profit Margin (Excl OI)
21.46%
21.09%
0.37%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 0.34% vs 5.91% in Dec 2025

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -5.30% vs -29.90% in Dec 2025

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
120.57
84.40
42.86%
Operating Profit (PBDIT) excl Other Income
23.85
16.09
48.23%
Interest
4.08
2.69
51.67%
Exceptional Items
0.00
0.00
Standalone Net Profit
10.98
4.21
160.81%
Operating Profit Margin (Excl OI)
19.78%
19.06%
0.72%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 42.86% vs 19.38% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 160.81% vs -47.51% in Mar 2024

stock-summaryCompany CV
About Asarfi Hospital Ltd stock-summary
stock-summary
Asarfi Hospital Ltd
Micro Cap
Hospital
Asarfi Hospital Limited was originally incorporated as Private Limited Company in the name of "Asarfi Hospital Private Limited" on October 4, 2005 issued by Registrar of Companies, Bihar & Jharkhand. Subsequently, status of the Company was converted into Public Limited and name of the Company was changed to "Asarfi Hospital Limited" vide a fresh Certificate of Incorporation dated February 08, 2012 issued by Registrar of Companies, Jharkhand.
Company Coordinates stock-summary
Icon
No Company Details Available